Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768772 | 1.00 | HDAC3 (0.39) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769473 | 0.91 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23768774 | 0.91 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769678 | 0.91 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769378 | 0.90 | HDAC3 (0.37) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769267 | 0.88 | KLKB1 (0.40) | KLKB1 | |
| SCHEMBL23843233 | 0.87 | HDAC3 (0.37) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769694 | 0.80 | KLKB1 (0.39) | HDAC4HDAC6KLKB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23769562 | 0.79 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC6KLKB1 | |
| SCHEMBL23769176 | 0.78 | PTGER2 (0.35) | KLKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | HDAC3 517/4885HDAC4 810/4885HDAC1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.